Drug Profile

Research programme: neurotrophin 3 based therapeutics - Otonomy

Alternative Names: NT-3

Latest Information Update: 01 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Otonomy
Class Analgesics; Antidementias; Antihyperglycaemics; Antiparkinsonians; Antivirals; Growth factors; Nerve growth factors; Neuroprotectants; Neuropsychotherapeutics; Proteins
Mechanism of Action Neuron stimulants; TrkB receptor agonists; TrkC receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 Mar 2023 Discontinued for Hearing loss in USA (unspecified route)
28 Mar 2023 No recent reports of development identified for research development in Hearing loss in USA
18 Feb 2019 Otonomy has patent protection for Trkb or trkc agonist compositions and methods for the treatment of otic conditions (WO 2017 0199 07A1)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com